Objective. To identify the risk factors associated with pregnancy failure in patients with APS treated with conventional therapy.
Introduction
The prognosis of pregnancies in patients with APS has greatly improved over the past two decades. Providing that appropriate treatment, usually based on heparin and/ or low-dose aspirin (LDA), is prescribed [1, 2] , 80% now conclude in the birth of healthy infants. Despite these encouraging statistics, many APS patients are, nonetheless, unable to give birth to healthy neonates [3] .
Lima et al. [4] reported that history of pregnancy loss and thrombocytopenia are both predictors of pregnancy failure. According to another study [5] , the use of aspirin before conception can be considered a significant, independent, prognostic factor associated with a favourable outcome, while an abnormal umbilical artery Doppler velocimetry in foetuses between 23 and 26 weeks of gestation appears to be predictive of pregnancy failure. Danowski et al. [6] recently demonstrated that pregnancy loss is more frequent in APS patients also affected with SLE than in women with APS alone. We have observed [7, 8] that different subsets of APS patients with history of pregnancy morbidity can be identified on the basis of their clinical and laboratory characteristics. In particular, women with previous thromboembolism and/or triple aPL positivity [LA plus Immunoglobulin (Ig) G aCL plus IgG anti-b 2 glycoprotein I (anti-b 2 GPI) antibodies] have been found to have a higher risk of unsuccessful pregnancy, whereas those with single (LA or aCL or anti-b 2 GPI) or double positivity (aCL plus anti-b 2 GPI) without thrombosis have a lower risk of complications during pregnancies managed with conventional treatment [8] . The persistence of uterine artery notching and lower complement C3 and C4 component levels have, moreover, been found to be independent predictors of lower neonatal birth weight and of birth at an earlier gestational age, whereas a false-positive IgM TORCH (Toxoplasma, rubella, CMV and herpes simplex virus tests) appears to be an independent predictor of lower neonatal birth weight [9] .
Identifying the risk factors associated with pregnancy failure could be an important step in aiding clinicians to manage pregnancies in these patients. Some patients, in fact, may require a personalized therapy strategy, in addition to standard protocols, to improve their chances for a successful outcome [10, 11] . As the studies carried out until now [49] have referred to small cohorts of APS patients, a casecontrol study drawing on a large multicentre cohort of conventionally treated pregnancies was designed and conducted to verify if specific laboratory profiles and/or clinical characteristics are predictive of unsuccessful pregnancy outcome.
Methods

Patients
We retrospectively considered 410 pregnancies of women attending six Italian Centres (Brescia, Milan, Padua, Pisa, Rome and Turin) and one Serbian Centre (Novi Sad), all being members of the European Forum on aPLs. All the women had been diagnosed with primary APS on the basis of the International Consensus Statement classification criteria [12] . During their pregnancies the women had been treated with conventional protocol treatments including LDA (100 mg) or heparin, alone or together. The study population consisted in those APS subjects who had a pregnancy failure, defined in accordance with the Sydney classification criteria [12] and thus with one or more of the following characteristics: (i) one or more unexplained fetal deaths of a morphologically normal foetus at or beyond the 10th week of gestation; (ii) one or more premature births of a morphologically normal neonate before the 34th week of gestation due to eclampsia or severe pre-eclampsia or signs of placental insufficiency; and (iii) three or more unexplained, consecutive, spontaneous abortions before the 10th week of gestation excluding causes due to maternal anatomical or hormonal abnormalities and paternal/maternal chromosomal abnormalities.
The control population consisted of APS women with successful pregnancies matched for age, anti-thrombotic therapy (LDA or heparin, alone or together; the drug dosage utilized; and the gestational age when therapy was begun) and additional treatment with steroids. The period examined was between 1988 and 2009 (median year 2003) for the APS patients with pregnancy failure and between 1986 and 2009 (median year 2005) for the patients with successful pregnancies. Pregnancies occurred in these APS patients before the studied pregnancy were untreated. The study was approved by the local ethics committee (ethics committee of University Hospital of Padua, Padua, Italy) and, in accordance with the principles laid down by the Declaration of Helsinki, the participants' medical records were reviewed after written informed consent was obtained. The following baseline data were registered and compared in the study and control populations: APS associated with SLE or other autoimmune diseases, mean disease duration of APS, mean disease duration of SLE or other autoimmune diseases, history of pregnancy morbidity or of thrombosis or of the two together, previous late fetal loss or premature birth or recurrent early abortion, more than one type of pregnancy morbidity, other APS-related manifestations (thrombocytopenia, epilepsy, headache, livedo reticularis, heart valve lesions and haemolytic anaemia), genetic risk factors for thrombosis (factor V Leiden, prothrombin G20210A mutation, decrease in C and S protein antigens and activities), acquired risk factors for thrombosis (hypertension, BMI 530 kg/m 2 ), aPL profile, other autoantibodies (ANAs, anti-dsDNA, anti-ENAs and anti-thyroid antibodies), low C3 and/or C4 levels (< 80 and 10 mg/dl, respectively), thrombocytopenia (platelet count <100 000/mm 3 ). The following data were registered at the end of pregnancies: demographic findings; treatment; type of pregnancy outcome; and maternal/fetal/ neonatal complications. Since we were interested in verifying if a decrease in C3 and/or C4 levels, a platelet count >20% lower than basal values or signs of placental thrombosis at the end of the pregnancies were associated with failure, we compared these parameters in the two study populations.
Antibody detection aCL and anti-b 2 GPI of IgG and IgM isotypes were determined by three of the centres using a home-made ELISA following the minimal requirements proposed by the European Forum on aPLs [13, 14] . The results of aCL testing were expressed as IgG phospholipid (GPL) or IgM phospholipid (MPL) using international reference material [15] . 
Laboratory characteristics
The laboratory features of all the women studied are reported in Table 2 . In particular, single aPL positivity was found in 14 APS patients with unsuccessful pregnancies ( 
Risk factors for pregnancy failure
As indicated in Tables 1 and 2 , at univariate analysis, the APS women with unsuccessful pregnancies had a significant prevalence of the following: SLE or other autoimmune diseases, thrombotic events, history of both pregnancy morbidity and vascular thrombosis, other APS-related manifestations, IgG anti-b 2 GPI antibodies, LA activity, triple aPL positivity, other autoantibodies, lower C3 and/or C4 levels both at baseline and at the time of pregnancy failure, a decreased platelet count (>20% with respect to the basal value) detected at the time of pregnancy failure and placental thrombosis. There was a significant prevalence of single aPL positivity and history of pregnancy morbidity alone, instead, in women with successful pregnancies. The independent features related, at multivariate analysis, to pregnancy failure were: the presence of SLE or other autoimmune diseases (OR 6.0; 95% CI 1.7, 20.8; P = 0.01), history of both thrombosis and pregnancy morbidity (OR 12.1; 95% CI 1.3, 115.3; P = 0.03) and triple aPL positivity (OR 4.1; 95% CI 1.0, 16.7; P = 0.05). The prevalence of the three risk factors in the two groups is summarized in Table 3 .
Discussion
This is the first casecontrol study, to our knowledge, aiming to investigate the risk factors for pregnancy failure in women diagnosed with definite APS treated with conventional therapy protocols. The clinical and laboratory features of APS patients attending seven centres were assessed. The study's most important finding was that there are three major independent risk factors for pregnancy failure in APS: (i) SLE or other autoimmune diseases; (ii) a history of both thromboembolism and pregnancy morbidity; and (iii) full (triple) aPL antibody positivity. SLE and history of thromboembolism are not novel risk factors for pregnancy morbidity, as some authors [6] have reported that the frequency of pregnancy loss is greater in APS associated with SLE than in primary APS. Others [7] have demonstrated that a history of thromboembolism predicts new thromboembolic events and new unsuccessful pregnancies. Yet others [8] have shown that triple aPL positivity is a marker of poor pregnancy outcome. What is novel about the present study is that all three parameters were found to be independent risk factors for poor pregnancy outcome in APS women with pregnancy failure, despite conventional treatment. These results could be clinically useful for pregnancy counselling and for treatment planning of these APS patients.
As far as aPL profiles are concerned, we confirm that single positivity is not a risk factor for pregnancy failure in treated patients [8] . We have found, in fact, that APS patients diagnosed on the basis of a single positive test generally have successful pregnancies when they are treated with conventional therapy. A history of pregnancy morbidity alone is, likewise, predictive of successful outcome provided that the patients are treated with conventional therapy. The type of previous pregnancy morbidity does not apparently affect the outcome of a new pregnancy. Congenital thrombophilia was, likewise, not correlated with pregnancy failure, although the number of positive cases may be too small for statistical analysis.
Other risk factors for pregnancy failure assessed by us were identified at univariate analysis. The first was lower C3 and C4 levels at baseline and at the time of pregnancy failure, both found to be significantly correlated with poor outcome. The role of complement activation in the pathogenesis of APS pregnancy morbidity is an intriguing question. Some authors [18, 19] have, in fact, demonstrated that activation of complement components C3, C4 and C5 increases the risk of injury or death of the embryo or foetus in animal models injected with aPL. Other investigators [20] have, moreover, found increased complement deposition (C4d and C3b) in placentas from aPL-positive women. Our results, in accordance with those of a recent, prospective cohort study [9] , seem to further contribute to defining the important role of the complement system in the pathogenesis of pregnancy failure in APS patients.
A platelet decrease (>20% of the baseline value) immediately preceding pregnancy failure is also significantly associated with pregnancy morbidity. As hypothesized in previous reports [10, 21] , it seems to be a very early sign of pregnancy complications, especially when it takes place during the first or second trimester.
Finally, placental intervillous thrombosis and infarction were significantly correlated with pregnancy failure in these patients. However, as reported in a recent review [22] , not all placentas from women with aPL-associated pregnancy failure show signs of infarction or placental vasculopathy. Some authors [23] have demonstrated, in fact, that placentas from aPL-positive women have histopathological signs of inflammation, supporting the hypothesis that thrombotic events are not the only pathogenic mechanism in APS patients with recurrent fetal loss.
Conclusion
The major independent risk factors for poor pregnancy outcome in pregnant APS women being treated with conventional therapy protocols are SLE or other autoimmune diseases, a history of both thrombosis and pregnancy morbidity, and triple aPL antibody positivity. APS patients with a history of pregnancy morbidity alone and/or a single aPL antibody positivity generally have successful pregnancies. Our study may, however, contain selection and information biases due to its retrospective and multicentric nature. If these findings are confirmed by large-scale prospective studies, prenatal counselling and therapeutic recommendations for APS patients planning to conceive will need to be differentiated on the basis of the clinical and laboratory features.
Rheumatology key messages
. There are three independent factors for poor outcome in conventionally treated pregnant APS women. . Previous pregnancy morbidity alone and/or a single aPL positivity are associated with successful pregnancies. 
